Efficacy of Adjunctive Treatments Added to Olanzapine or Clozapine for Weight Control in Patients with Schizophrenia: A Systematic Review and Meta-Analysis

Objectives. This study was conducted to review systematically adjunctive treatments for weight reduction in patients with schizophrenia and compare efficacies of clinical trials through meta-analysis, so as to provide effective clinical guideline regarding weight control for patients taking atypical antipsychotics. Methods. Candidate clinical trials were identified through searching the Cochrane Central Register of Controlled Trials, PubMed, and PsycINFO. Fourteen randomized clinical trials were included for systematic review and meta-analysis from 132 potential trials. The Comprehensive Meta-Analysis version 2 was used for meta-analysis. Results. Difference in means and significances from meta-analyses regarding weight control by adjunctive treatments showed that topiramate, aripiprazole, or sibutramine was more effective than metformin or reboxetine. Psychiatric evaluations did not show statistically significant changes between treatment groups and placebo groups except topiramate adjunctive treatments. Adverse effects regarding adjunctive therapies were tolerable and showed statistically no significances compared to control groups. Conclusion. Though having several reports related to exacerbation of psychiatric symptoms, topiramate and aripiprazole are more efficacious than other medications in regard to weight reduction and less burden of critical adverse effects as well as being beneficial for clinical improvement.

• Publication year

  2015

• Venue

  TheScientificWorldJournal

• Publication date

  2015-01-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1155/2015/970730PMID 25664341PMCID 4310265
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sibutramine on Cardiovascular Outcome

  2011cited by this paper
• Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis.

  2011cited by this paper
• Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study

  2011cited by this paper
• Topiramate Augmentation in Clozapine-Treated Patients With Schizophrenia: Clinical and Metabolic Effects

  2010cited by this paper
• Effectiveness of Medications Used to Attenuate Antipsychotic-Related Weight Gain and Metabolic Abnormalities: A Systematic Review and Meta-Analysis

  2010cited by this paper
• Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial.

  2010cited by this paper
• Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.

  2010cited by this paper
• Aripiprazole Added to Overweight and Obese Olanzapine-Treated Schizophrenia Patients

  2009cited by this paper
• Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial

  2009cited by this paper
• Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study.

  2009cited by this paper
• Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care

  2008cited by this paper
• Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.

  2008cited by this paper
• Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.

  2008cited by this paper
• A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.

  2008cited by this paper
• Topiramate-induced weight loss in schizophrenia: a retrospective case series study.

  2007cited by this paper
• Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study

  2007cited by this paper
• Is clozapine—aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?

  2007cited by this paper
• Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial.

  2007cited by this paper
• A double‐blind, placebo‐controlled trial of sibutramine for clozapine‐associated weight gain

  2007cited by this paper
• Metformin for Prevention of Weight Gain and Insulin Resistance with Olanzapine: A Double-Blind Placebo-Controlled Trial

  2006cited by this paper
• Efficacy of Topiramate, Valproate, and Their Combination on Aggression/Agitation Behavior in Patients With Psychosis

  2006cited by this paper
• Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis

  2005cited by this paper
• A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.

  2005cited by this paper
• Profound weight loss associated with reboxetine use in a 44-year-old woman.

  2005cited by this paper
• The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study.

  2004cited by this paper
• Comparison of the Treatment with Paroxetine and Reboxetine in Panic Disorder: A Randomized, Single-Blind Study

  2004cited by this paper
• H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs

  2003cited by this paper
• Predictors of weight loss in adults with topiramate-treated epilepsy.

  2003cited by this paper
• Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.

  2003cited by this paper
• Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial.

  2003cited by this paper
• Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition.

  2002cited by this paper
• Body Mass Index in Persons with Schizophrenia

  2001cited by this paper
• Double Blind

  2001cited by this paper
• Efficacy of Topiramate

  1998cited by this paper
• and as an in

  year unknowninfluential reference
• AND T

  year unknowncited by this paper

• The role of mental health in obesity management.

  2025cites this paper
• Pharmacological interventions to manage cardiometabolic outcomes in adults with severe mental illness: umbrella review.

  2025cites this paper
• Aripiprazole Augmentation as a Treatment for Clozapine-Induced Weight Gain.

  2024cites this paper
• Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry)

  2023cites this paper
• Partial agonists of dopamine receptors: clinical effects and dopamine receptor interactions in combining aripiprazole with a full antagonist in treating psychosis

  2023cites this paper
• Use of the Third-Generation Atypical Antipsychotic Aripiprazole (Zylaxera®) for Treatment of Depressive States in Schizophrenia: Efficacy and Safety Study

  2023cites this paper
• The development and benefits of metformin in various diseases

  2023cites this paper
• The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets

  2022cites this paper
• Aripiprazole: Examining the Clinical Implications of D2 Affinity

  2022cites this paper
• Samidorphan for the treatment of weight gain associated with olanzapine in patients with schizophrenia and bipolar disorder

  2022cites this paper
• The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?

  2022cites this paper
• The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets

  2022cites this paper
• High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?

  2021cites this paper
• A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine

  2021cites this paper
• Outcomes and safety of concomitant topiramate or metformin for antipsychotics-induced obesity: a randomized-controlled trial

  2020cites this paper
• Adjunctive metformin for antipsychotic-induced dyslipidemia: a meta-analysis of randomized, double-blind, placebo-controlled trials

  2020cites this paper
• How and when to treat the most common adverse effects of antipsychotics: Expert review from research to clinical practice

  2020cites this paper
• The Role of Mental Health in Obesity Management

  2020cites this paper
• Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.

  2019cites this paper
• Topiramate mitigates weight gain in antipsychotic-treated patients with schizophrenia: meta-analysis of randomised controlled trials

  2019influential citation
• New discoveries for an old drug: a review of recent olanzapine research

  2019cites this paper
• Metabolic risk reduction in patients with schizophrenia treated with antipsychotics: recommendations of the Polish Psychiatric Association.

  2019cites this paper
• Adjunctive Reboxetine for Schizophrenia: Meta-analysis of Randomized Double-blind, Placebo-controlled Trials

  2019cites this paper
• University of Birmingham Topiramate and metformin are effective add-on treatments in controlling antipsychotic-induced weight gain

  2018cites this paper
• University of Topiramate and metformin are effective add-on treatments in controlling antipsychotic-induced weight gain

  2018cites this paper
• Glucagon-like peptide-1 receptor agonists as an effective therapeutic agent for diabetes mellitus and obesity in patients with schizophrenia under treatment with second-generation antipsychotics

  2018cites this paper
• Topiramate and Metformin Are Effective Add-On Treatments in Controlling Antipsychotic-Induced Weight Gain: A Systematic Review and Network Meta-Analysis

  2018cites this paper
• Clinical Trials and Therapeutic Rationale for Drug Repurposing in Schizophrenia.

  2018cites this paper
• A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers

  2017cites this paper
• Metabolic outcomes of bergamot polyphenolic fraction administration in patients treated with second-generation antipsychotics: a pilot study.

  2017cites this paper
• Effect of adjunctive ranitidine for antipsychotic-induced weight gain: A systematic review of randomized placebo-controlled trials

  2017cites this paper
• Maslinic acid ameliorates NMDA receptor blockade‐induced schizophrenia‐like behaviors in mice

  2017cites this paper
• Efficacy and safety of adjunctive topiramate for schizophrenia: a meta‐analysis of randomized controlled trials

  2016cites this paper
• Chapter 5 - Antipsychotic Drugs

  2016cites this paper
• Metabolic adverse effects in clozapine-treated patients with schizophrenia : Cytokine and adipokine alterations, neuropeptide Y, and genetic associations

  2016cites this paper
• Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis

  2016cites this paper
• Selective noradrenaline reuptake inhibitors for schizophrenia.

  2012cites this paper
• The Role of Mental Health in Obesity

  year unknowncites this paper